Related Experiment Video
Updated: Jun 21, 2025
09:45
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
Transfer behaviors in stroke and dementia development associated with environmental risks.
Kung-Min Wang1, Shih-Hsien Tseng1, Chia-Min Lee1
1Department of Industrial Management, National Taiwan University of Science and Technology, Taipei, Taiwan.
Geriatrics & Gerontology International
|July 15, 2024
Summary
Chronic diseases and environmental factors significantly impact stroke and dementia transitions. Key influences include sex, age, unemployment, and air pollution, highlighting risks for males under 65.
Area of Science:
- Medical Informatics
- Environmental Informatics
- Public Health
Background:
- Chronic diseases are major contributors to stroke, dementia, and mortality.
- Environmental risks are increasingly recognized as factors in stroke-to-dementia transitions.
- Understanding these transitions is crucial for public health interventions.
Purpose of the Study:
- To investigate the transition behaviors from chronic diseases to stroke and from stroke to dementia.
- To evaluate the influence of chronic diseases and environmental risk factors on these transitions.
- To identify high-risk subpopulations for stroke and subsequent dementia.
Main Methods:
- An integrated survey of medical and environmental informatics data from 10,627 stroke patients in Taiwan.
- Application of covariate models and subgroup analysis.
- Assessment of chronic diseases and environmental factors (divorce, unemployment, solitariness, temperature, air pollution).
Main Results:
- 98 covariate models were constructed, analyzing 14 transition types.
- 26 out of 98 transitions were statistically significant.
- Sex, age, divorce rate, unemployment rate, temperature, and air pollution influenced chronic disease to stroke transitions.
- Sex, age, unemployment rate, and temperature influenced stroke to dementia transitions.
Conclusions:
- Environmental factors and demographic variables significantly influence disease progression pathways.
- Males aged 65 and below represent a high-risk group for stroke and dementia.
- Findings underscore the need for targeted interventions considering both clinical and environmental factors.
Related Concept Videos
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
01:15Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
01:30Cognitive Development During Adulthood
83
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
83
01:22Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177